{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T01:47:37Z","timestamp":1772502457521,"version":"3.50.1"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T00:00:00Z","timestamp":1630540800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"EOSC-Life","award":["824087"],"award-info":[{"award-number":["824087"]}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["716063"],"award-info":[{"award-number":["716063"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","award":["317680"],"award-info":[{"award-number":["317680"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chemosensitivity assays are commonly used for preclinical drug discovery and clinical trial optimization. However, data from independent assays are often discordant, largely attributed to uncharacterized variation in the experimental materials and protocols. We report here the launching of Minimal Information for Chemosensitivity Assays (MICHA), accessed via https:\/\/micha-protocol.org. Distinguished from existing efforts that are often lacking support from data integration tools, MICHA can automatically extract publicly available information to facilitate the assay annotation including: 1) compounds, 2) samples, 3) reagents and 4) data processing methods. For example, MICHA provides an integrative web server and database to obtain compound annotation including chemical structures, targets and disease indications. In addition, the annotation of cell line samples, assay protocols and literature references can be greatly eased by retrieving manually curated catalogues. Once the annotation is complete, MICHA can export a report that conforms to the FAIR principle (Findable, Accessible, Interoperable and Reusable) of drug screening studies. To consolidate the utility of MICHA, we provide FAIRified protocols from five major cancer drug screening studies as well as six recently conducted COVID-19 studies. With the MICHA web server and database, we envisage a wider adoption of a community-driven effort to improve the open access of drug sensitivity assays.<\/jats:p>","DOI":"10.1093\/bib\/bbab350","type":"journal-article","created":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T15:47:18Z","timestamp":1628524038000},"source":"Crossref","is-referenced-by-count":13,"title":["Minimal information for chemosensitivity assays (MICHA): a next-generation pipeline to enable the FAIRification of drug screening experiments"],"prefix":"10.1093","volume":"23","author":[{"given":"Ziaurrehman","family":"Tanoli","sequence":"first","affiliation":[{"name":"Research Program in Systems Oncology, Faculty of medicine, University of Helsinki, Finland"}]},{"given":"Jehad","family":"Aldahdooh","sequence":"additional","affiliation":[{"name":"Research Program in Systems Oncology, Faculty of medicine, University of Helsinki, Finland"}]},{"given":"Farhan","family":"Alam","sequence":"additional","affiliation":[{"name":"Research Program in Systems Oncology, Faculty of medicine, University of Helsinki, Finland"}]},{"given":"Yinyin","family":"Wang","sequence":"additional","affiliation":[{"name":"Research Program in Systems Oncology, Faculty of medicine, University of Helsinki, Finland"}]},{"given":"Umair","family":"Seemab","sequence":"additional","affiliation":[{"name":"Research Program in Systems Oncology, Faculty of medicine, University of Helsinki, Finland"}]},{"given":"Maddalena","family":"Fratelli","sequence":"additional","affiliation":[{"name":"Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Italy"}]},{"given":"Petr","family":"Pavlis","sequence":"additional","affiliation":[{"name":"Institute of Molecular and Translational Medicine, Czech"}]},{"given":"Marian","family":"Hajduch","sequence":"additional","affiliation":[{"name":"Institute of Molecular and Translational Medicine, Czech"}]},{"given":"Florence","family":"Bietrix","sequence":"additional","affiliation":[{"name":"European Infrastructure for Translational Medicine, UK"}]},{"given":"Philip","family":"Gribbon","sequence":"additional","affiliation":[{"name":"Fraunhofer Institute for Molecular Biology and Applied Ecology, Germany"}]},{"given":"Andrea","family":"Zaliani","sequence":"additional","affiliation":[{"name":"Fraunhofer Institute for Molecular Biology and Applied Ecology, Germany"}]},{"given":"Matthew D","family":"Hall","sequence":"additional","affiliation":[{"name":"National Center for Advancing Translational Sciences, USA"}]},{"given":"Min","family":"Shen","sequence":"additional","affiliation":[{"name":"National Center for Advancing Translational Sciences, USA"}]},{"given":"Kyle","family":"Brimacombe","sequence":"additional","affiliation":[{"name":"National Center for Advancing Translational Sciences, USA"}]},{"given":"Evgeny","family":"Kulesskiy","sequence":"additional","affiliation":[{"name":"Institute for Molecular Medicine Finland, University of Helsinki, Finland"}]},{"given":"Jani","family":"Saarela","sequence":"additional","affiliation":[{"name":"Institute for Molecular Medicine Finland, University of Helsinki, Finland"}]},{"given":"Krister","family":"Wennerberg","sequence":"additional","affiliation":[{"name":"Biotech Research & Innovation Centre (BRIC), University of Copenhagen, Denmark"}]},{"given":"Markus","family":"V\u00e4h\u00e4-Koskela","sequence":"additional","affiliation":[{"name":"Institute for Molecular Medicine Finland, University of Helsinki, Finland"}]},{"given":"Jing","family":"Tang","sequence":"additional","affiliation":[{"name":"Research Program in Systems Oncology, Faculty of medicine, University of Helsinki, Finland"}]}],"member":"286","published-online":{"date-parts":[[2021,9,1]]},"reference":[{"key":"2022011921010090700_ref1","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1158\/0008-5472.CAN-14-0725","article-title":"Enhancing reproducibility in cancer drug screening: how do we move forward?","volume":"74","author":"Hatzis","year":"2014","journal-title":"Cancer Res"},{"key":"2022011921010090700_ref2","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature17987","article-title":"Reproducible pharmacogenomic profiling of cancer cell line panels","volume":"533","author":"Haverty","year":"2016","journal-title":"Nature"},{"key":"2022011921010090700_ref3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-62848-5","article-title":"Optimization of cell viability assays to improve replicability and reproducibility of cancer drug sensitivity screens","volume":"10","author":"Larsson","year":"2020","journal-title":"Sci Rep"},{"key":"2022011921010090700_ref4","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/nbt.1411","article-title":"Promoting coherent minimum reporting guidelines for biological and biomedical investigations: the MIBBI project","volume":"26","author":"Taylor","year":"2008","journal-title":"Nat Biotechnol"},{"key":"2022011921010090700_ref5","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nrd3503","article-title":"Minimum information about a bioactive entity (MIABE)","volume":"10","author":"Orchard","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"2022011921010090700_ref6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2041-1480-5-S1-S5","article-title":"Evolving BioAssay ontology (BAO): modularization, integration and applications","volume":"5","author":"Abeyruwan","year":"2014","journal-title":"J Biomed Semantics"},{"key":"2022011921010090700_ref7","doi-asserted-by":"crossref","first-page":"D930","DOI":"10.1093\/nar\/gky1075","article-title":"ChEMBL: towards direct deposition of bioassay data","volume":"47","author":"Mendez","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"2022011921010090700_ref8","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cell.2016.06.017","article-title":"A landscape of pharmacogenomic interactions in cancer","volume":"166","author":"Iorio","year":"2016","journal-title":"Cell"},{"key":"2022011921010090700_ref9","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nature11003","article-title":"The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"483","author":"Barretina","year":"2012","journal-title":"Nature"},{"key":"2022011921010090700_ref10","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1158\/2159-8290.CD-15-0235","article-title":"Harnessing connectivity in a large-scale small-molecule sensitivity dataset","volume":"5","author":"Seashore-Ludlow","year":"2015","journal-title":"Cancer Discov"},{"key":"2022011921010090700_ref11","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01218-20","article-title":"Broad anti-coronavirus activity of food and drug administration-approved drugs against SARS-CoV-2 in vitro and SARS-CoV in vivo","volume":"94","author":"Weston","year":"2020","journal-title":"J Virol"},{"key":"2022011921010090700_ref12","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41586-020-2286-9","article-title":"A SARS-CoV-2 protein interaction map reveals targets for drug repurposing","volume":"583","author":"Gordon","year":"2020","journal-title":"Nature"},{"key":"2022011921010090700_ref13","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-70143-6","article-title":"In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication","volume":"10","author":"Touret","year":"2020","journal-title":"Sci Rep"},{"key":"2022011921010090700_ref14","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00819-20","article-title":"Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs","volume":"64","author":"Jeon","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2022011921010090700_ref15","article-title":"An OpenData portal to share COVID-19 drug repurposing data in real time","volume":"2020.06.04","author":"Brimacombe","year":"2020","journal-title":"bioRxiv"},{"key":"2022011921010090700_ref16","doi-asserted-by":"crossref","DOI":"10.1038\/s41597-021-00848-4","article-title":"A SARS-CoV-2 cytopathicity dataset generated by high-content screening of a large drug repurposing collection","volume-title":"Sci Data","author":"Ellinger","year":"2021"},{"key":"2022011921010090700_ref17","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/978-1-4939-7493-1_17","article-title":"Methods for high-throughput drug combination screening and synergy scoring","author":"He","year":"2018","journal-title":"Cancer Syst Biol"},{"key":"2022011921010090700_ref18","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/annonc\/mdw660","article-title":"Network-guided modeling allows tumor-type independent prediction of sensitivity to all-trans-retinoic acid","volume":"28","author":"Bolis","year":"2017","journal-title":"Ann Oncol"},{"key":"2022011921010090700_ref19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/database\/bay083","article-title":"Drug target commons 2.0: a community platform for systematic analysis of drug\u2013target interaction profiles","volume":"2018","author":"Tanoli","year":"2018","journal-title":"Database"},{"key":"2022011921010090700_ref20","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.chembiol.2017.11.009","article-title":"Drug target commons: a community effort to build a consensus Knowledge Base for drug-target interactions","volume":"25","author":"Tang","year":"2018","journal-title":"Cell Chem Biol"},{"key":"2022011921010090700_ref21","doi-asserted-by":"crossref","first-page":"D1045","DOI":"10.1093\/nar\/gkv1072","article-title":"BindingDB in 2015: a public database for medicinal chemistry, computational chemistry and systems pharmacology","volume":"44","author":"Gilson","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"2022011921010090700_ref22","doi-asserted-by":"crossref","first-page":"D945","DOI":"10.1093\/nar\/gkw1074","article-title":"The ChEMBL database in 2017","volume":"45","author":"Gaulton","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"2022011921010090700_ref23","doi-asserted-by":"crossref","first-page":"S1\u2013S16","DOI":"10.1111\/bph.13877","article-title":"The concise guide to pharmacology 2017\/18: overview","volume":"174","author":"Alexander","year":"2017","journal-title":"Br J Pharmacol"},{"key":"2022011921010090700_ref24","doi-asserted-by":"crossref","first-page":"D1036\u201344","DOI":"10.1093\/nar\/gkv1165","article-title":"DGIdb 2.0: mining clinically relevant drug\u2013gene interactions","volume":"44","author":"Wagner","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"2022011921010090700_ref25","doi-asserted-by":"crossref","first-page":"D668","DOI":"10.1093\/nar\/gkj067","article-title":"DrugBank: a comprehensive resource for in silico drug discovery and exploration","volume":"34","author":"Wishart","year":"2006","journal-title":"Nucleic Acids Res"},{"key":"2022011921010090700_ref26","doi-asserted-by":"crossref","first-page":"25\u201338","DOI":"10.7171\/jbt.18-2902-002","article-title":"The cellosaurus, a cell-line knowledge resource","volume":"29","author":"Bairoch","year":"2018","journal-title":"J Biomol Tech"},{"key":"2022011921010090700_ref27","doi-asserted-by":"crossref","first-page":"i509","DOI":"10.1093\/bioinformatics\/bty277","article-title":"Learning with multiple pairwise kernels for drug bioactivity prediction","volume":"34","author":"Cichonska","year":"2018","journal-title":"Bioinformatics"},{"key":"2022011921010090700_ref28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1005678","article-title":"Computational-experimental approach to drug-target interaction mapping: a case study on kinase inhibitors","volume":"13","author":"Cichonska","year":"2017","journal-title":"PLoS Comput Biol"},{"key":"2022011921010090700_ref29","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1093\/bioinformatics\/btaa010","article-title":"Network-based prediction of drug\u2013target interactions using an arbitrary-order proximity embedded deep forest","volume":"36","author":"Zeng","year":"2020","journal-title":"Bioinformatics"},{"key":"2022011921010090700_ref30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41540-019-0098-z","article-title":"Network pharmacology modeling identifies synergistic Aurora B and ZAK interaction in triple-negative breast cancer","volume":"5","author":"Tang","year":"2019","journal-title":"NPJ Syst Biol Appl"},{"key":"2022011921010090700_ref31","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/s41467-019-09186-x","article-title":"Network-based prediction of drug combinations","volume":"10","author":"Cheng","year":"2019","journal-title":"Nat Commun"},{"key":"2022011921010090700_ref32","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","article-title":"Selumetinib in children with inoperable plexiform neurofibromas","volume":"382","author":"Gross","year":"2020","journal-title":"N Engl J Med"},{"key":"2022011921010090700_ref33","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1158\/1078-0432.CCR-11-1000","article-title":"Hsp90 molecular chaperone inhibitors: are we there yet?","volume":"18","author":"Neckers","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2022011921010090700_ref34","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbaa003","article-title":"Exploration of databases and methods supporting drug repurposing: a comprehensive survey","volume":"22","author":"Tanoli","year":"2021","journal-title":"Brief Bioinform"}],"container-title":["Briefings in Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bib\/article-pdf\/23\/1\/bbab350\/42229873\/bbab350.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bib\/article-pdf\/23\/1\/bbab350\/42229873\/bbab350.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T16:01:40Z","timestamp":1642608100000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bib\/article\/doi\/10.1093\/bib\/bbab350\/6361039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1,17]]}},"URL":"https:\/\/doi.org\/10.1093\/bib\/bbab350","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.12.03.409409","asserted-by":"object"}]},"ISSN":["1467-5463","1477-4054"],"issn-type":[{"value":"1467-5463","type":"print"},{"value":"1477-4054","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1]]},"published":{"date-parts":[[2021,9,1]]},"article-number":"bbab350"}}